Components:
Medically reviewed by Fedorchenko Olga Valeryevna, PharmD. Last updated on 15.04.2022
Attention! Information on this page is intended only for medical professionals! Information is collected in open sources and may contain significant errors! Be careful and double-check all the information on this page!
Top 20 medicines with the same components:
Trimipramin-neuraxpharm 25mg is indicated for the relief of symptoms of depression. Endogenous depression is more likely to be alleviated than other depressive states. In studies with neurotic outpatients, the drug appeared to be equivalent to amitriptyline in the less-depressed patients but somewhat less effective than amitriptyline in the more severely depressed patients. In hospitalized depressed patients, Trimipramin-neuraxpharm 25mg and imipramine were equally effective in relieving depression.
Trimipramin-neuraxpharm 25mg is a tricyclic antidepressant. Trimipramin-neuraxpharm 25mg affects chemicals in the brain that may become unbalanced.
Trimipramin-neuraxpharm 25mg is used to treat symptoms of depression.
Trimipramin-neuraxpharm 25mg may also be used for purposes not listed in this medication guide.
Dosage should be initiated at a low level and increased gradually, noting carefully the clinical response and any evidence of intolerance.
Lower dosages are recommended for elderly patients and adolescents. Lower dosages are also recommended for outpatients as compared to hospitalized patients who will be under close supervision. It is not possible to prescribe a single dosage schedule of Trimipramin-neuraxpharm 25mg that will be therapeutically effective in all patients. The physical psychodynamic factors contributing to depressive symptomatology are very complex; spontaneous remissions or exacerbations of depressive symptoms may occur with or without drug therapy. Consequently, the recommended dosage regimens are furnished as a guide which may be modified by factors such as the age of the patient, chronicity and severity of the disease, medical condition of the patient, and degree of psychotherapeutic support.
Most antidepressant drugs have a lag period of ten days to four weeks before a therapeutic response is noted. Increasing the dose will not shorten this period but rather increase the incidence of adverse reactions.
Usual Adult Dose
Outpatients and Office Patients
Initially, 75 mg/day in divided doses, increased to 150 mg/day. Dosages over 200 mg/day are not recommended. Maintenance therapy is in the range of 50 to 150 mg/day. For convenient therapy and to facilitate patient compliance, the total dosage requirement may be given at bedtime.
Hospitalized Patients
Initially, 100 mg/day in divided doses. This may be increased gradually in a few days to 200 mg/day, depending upon individual response and tolerance. If improvement does not occur in 2 to 3 weeks, the dose may be increased to the maximum recommended dose of 250 to 300 mg/day.
Adolescent and Geriatric Patients
Initially, a dose of 50 mg/day is recommended, with gradual increments up to 100 mg/day, depending upon patient response and tolerance.
Maintenance
Following remission, maintenance medication may be required for a longer period of time, at the lowest dose that will maintain remission. Maintenance therapy is preferably administered as a single dose at bedtime. To minimize relapse, maintenance therapy should be continued for about three months.
Switching a Patient To or From a Monoamine Oxidas e Inhibitor (MAOI) Intended to Treat Psychiatric Disorders
At least 14 days should elapse between discontinuation of an MAOI intended to treat psychiatric disorders and initiation of therapy with Trimipramin-neuraxpharm 25mg. Conversely, at least 14 days should be allowed after stopping Trimipramin-neuraxpharm 25mg before starting an MAOI intended to treat psychiatric disorders.
Use of Trimipramin-neuraxpharm 25mg With Other MAOIs, Such as Linezolid or Methylene Blue
Do not start Trimipramin-neuraxpharm 25mg in a patient who is being treated with linezolid or intravenous methylene blue because there is increased risk of serotonin syndrome. In a patient who requires more urgent treatment of a psychiatric condition, other interventions, including hospitalization, should be considered.
In some cases, a patient already receiving therapy with Trimipramin-neuraxpharm 25mg may require urgent treatment with linezolid or intravenous methylene blue. If acceptable alternatives to linezolid or intravenous methylene blue treatment are not available and the potential benefits of linezolid or intravenous methylene blue treatment are judged to outweigh the risks of serotonin syndrome in a particular patient, Trimipramin-neuraxpharm 25mg should be stopped promptly, and linezolid or intravenous methylene blue can be administered. The patient should be monitored for symptoms of serotonin syndrome for 2 weeks or until 24 hours after the last dose of linezolid or intravenous methylene blue, whichever comes first. Therapy with Trimipramin-neuraxpharm 25mg may be resumed 24 hours after the last dose of linezolid or intravenous methylene blue.
The risk of administering methylene blue by non-intravenous routes (such as oral tablets or by local injection) or in intravenous doses much lower than 1 mg/kg with Trimipramin-neuraxpharm 25mg is unclear. The clinician should, nevertheless, be aware of the possibility of emergent symptoms of serotonin syndrome with should, nevertheless, be aware of the possibility of emergent symptoms of serotonin syndrome with such use.
How supplied
Trimipramin-neuraxpharm 25mg (Trimipramin-neuraxpharm 25mg maleate) Capsules
25 mg — Opaque blue and yellow capsule in bottles of 100 (NDC 51285-538-02).
Printed OP and 718
50 mg — Opaque blue and orange capsule in bottles of 100 (NDC 51285-539-02).
Printed OP and 719
100 mg — Opaque blue and white capsule in bottles of 100 (NDC 51285-554-02).
Printed OP and 720
Store at 20°-25°C (68°-77°F).
Keep bottles tightly closed.
Dispense in a tight container.
Teva Select Brands, Horsham, PA 19044, Division of Teva Pharmaceuticals USA, Inc. Revised: May 2014
See also:
What is the most important information I should know about Trimipramin-neuraxpharm 25mg?
Monoamine Oxidase Inhibitors (MAOIs)
The use of MAOIs intended to treat psychiatric disorders with Trimipramin-neuraxpharm 25mg or within 14 days of stopping treatment with Trimipramin-neuraxpharm 25mg is contraindicated because of an increased risk of serotonin syndrome. The use of Trimipramin-neuraxpharm 25mg within 14 days of stopping an MAOI intended to treat psychiatric disorders is also contraindicated.
Starting Trimipramin-neuraxpharm 25mg in a patient who is being treated with MAOIs such as linezolid or intravenous methylene blue is also contraindicated because of an increased risk of serotonin syndrome.
Hypersensitivity to Tricyclic Antidepressants
Cross-sensitivity between Trimipramin-neuraxpharm 25mg and other dibenzazepines is a possibility.
Myocardial Infarction
The drug is contraindicated during the acute recovery period after a myocardial infarction.
Use Trimipramin-neuraxpharm 25mg as directed by your doctor. Check the label on the medicine for exact dosing instructions.
- Trimipramin-neuraxpharm 25mg comes with an extra patient information sheet called a Medication Guide. Read it carefully. Read it again each time you get Trimipramin-neuraxpharm 25mg refilled.
- Take Trimipramin-neuraxpharm 25mg by mouth with or without food.
- Taking Trimipramin-neuraxpharm 25mg at bedtime may help reduce side effects (eg, daytime drowsiness). Discuss this possibility with your doctor.
- It may take 1 to 3 weeks before you notice the effect of Trimipramin-neuraxpharm 25mg. Continue to use Trimipramin-neuraxpharm 25mg even if you feel well. Do not miss any doses.
- If you miss a dose of Trimipramin-neuraxpharm 25mg, take it as soon as possible. If it is almost time for your next dose, skip the missed dose and go back to your regular dosing schedule. Do not take 2 doses at once. If you take 1 dose daily at bedtime, do not take the missed dose the next morning.
Ask your health care provider any questions you may have about how to use Trimipramin-neuraxpharm 25mg.
There are specific as well as general uses of a drug or medicine. A medicine can be used to prevent a disease, treat a disease over a period or cure a disease. It can also be used to treat the particular symptom of the disease. The drug use depends on the form the patient takes it. It may be more useful in injection form or sometimes in tablet form. The drug can be used for a single troubling symptom or a life-threatening condition. While some medications can be stopped after few days, some drugs need to be continued for prolonged period to get the benefit from it.Trimipramin-neuraxpharm 25mg is used in adults and elderly to treat depression, especially in people who also have sleeping problems, anxiety, irritability and restlessness.
See also:
What other drugs will affect Trimipramin-neuraxpharm 25mg?
Decreased antihypertensive effects of guanethidine, guanfacine, debrisoquine, betanidine and possibly clonidine. Increased CNS depression with CNS depressants such as alcohol, sedatives, hypnotics or barbiturates. Increased Trimipramin-neuraxpharm 25mg levels with protease inhibitors, SSRIs, selegiline, tramadol, quinidine, diltiazem and verapamil. Decreased Trimipramin-neuraxpharm 25mg levels with barbiturates. Increased risk of arrhythmias with drugs that prolong QT intervals. Increased risk of serotonin syndrome with linezolid. Increased antimuscarinic adverse effects with nefopam. Risk of neurotoxicity and serotonin syndrome with lithium.
Potentially Fatal: Not to be given concurrently with, or within 2 wk of cessation of, therapy with MAOI and MAOI should be restarted at least 7-14 days after Trimipramin-neuraxpharm 25mg has been stopped. Exaggerated response such as hypertension, cardiac arrhythmias with sympathomimetic drugs.
See also:
What are the possible side effects of Trimipramin-neuraxpharm 25mg?
Note: The pharmacological similarities among the tricyclic antidepressants require that each of the reactions be considered when Trimipramin-neuraxpharm 25mg is administered. Some of the adverse reactions included in this listing have not in fact been reported with Trimipramin-neuraxpharm 25mg.
Cardiovascular: Hypotension, hypertension, tachycardia, palpitation, myocardial infarction, arrhythmias, heart block and stroke.
Psychiatric: Confusional states (especially the elderly) with hallucinations, disorientation, delusions, anxiety, restlessness, agitation, insomnia and nightmare, hypomania, exacerbation of psychoses.
Neurological: Numbness, tingling, paresthesias of extremities, incoordination, ataxia, tremors, peripheral neuropathy, extrapyramidal symptoms, seizures, alterations in EEG patterns, tinnitus, syndrome of inappropriate antidiuretic hormone (ADH) secretion.
Anticholinergic: Dry mouth and rarely associated sublingual adenitis, blurred vision, disturbances of accommodation, mydriasis, constipation, paralytic ileus, urinary retention, delayed micturition and dilation of the urinary tract.
Allergic: Skin rash, reptechiae, urticaria, itching, photosensitization, edema of the tongue and face.
Hematologic: Bone marrow depression including agranulocytosis, eosinophilia, purpura, thrombocytopenia, leukocyte and differential counts should be performed in any patients who develops fever and sore throat during therapy; Trimipramin-neuraxpharm 25mg should be discontinued if there is evidence of pathological neutrophil depression.
Gastrointestinal: Nausea and vomiting, anorexia, epigastric distress, diarrhea, peculiar taste, stomatitis, abdominal cramps and black tongue.
Endocrine: Gynecomastia in the male, breast enlargement and galactorrhea in the female; increased or decreased libido; impotence; testicular swelling and elevation or depression of blood sugar levels.
Other: Jaundice (simulating obstructive); altered liver function; weight gain or loss; perspiration; flushing; urinary frequency; drowsiness, dizziness, weakness and fatigue, headache, parotid swelling; alopecia.
Withdrawal Symptoms: Though not indicative of addiction, abrupt cessation of treatment after prolonged therapy may produce nausea, headache and malaise.
Tricyclic antidepressant similar to imipramine, but with more antihistaminic and sedative properties. [PubChem]
However, we will provide data for each active ingredient